Self-Treat Vagus Nerve Stimulator Shows Promise For Cluster Headaches
This article was originally published in The Gray Sheet
A one-year open-label study published in Neurology suggests that electroCore’s gammaCore non-invasive vagus nerve stimulation system could be a practical therapy for chronic cluster headaches.
You may also be interested in...
Armed with financing from a syndicate including Merck’s Global Health Innovation Fund, electroCore is pressing ahead with pivotal trials in several headache indications, with other neural and immune conditions to follow. The company believes its noninvasive vagus nerve stimulator that is self-administered by the patient could potentially upturn treatment paradigms.
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.